Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Neuroendocrine Carcinoma, Grade 3”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Early research (Phase 1)Active Not RecruitingNCT02088645
What this trial is testing

177Lu-PP-F11N for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer.

Who this might be right for
Thyroid Cancer, MedullaryNeuroendocrine Tumor of the Lung Grade 1 and 2Neuroendocrine Tumor of the Thymus Grade 1 and 2+1 more
University Hospital, Basel, Switzerland 24
Testing effectiveness (Phase 2)Study completedNCT03278405
What this trial is testing

Avelumab in G3 NEC

Who this might be right for
Neuroendocrine Carcinoma
Sunnybrook Health Sciences Centre 10
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)Study completedNCT02113800
What this trial is testing

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study

Who this might be right for
Poorly Differentiated Malignant Neuroendocrine CarcinomaNeuroendocrine Carcinoma, Grade 3Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3+2 more
AIO-Studien-gGmbH
Testing effectiveness (Phase 2)UnknownNCT00637637
What this trial is testing

External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases

Who this might be right for
Cancer
Oncology Institute of Southern Switzerland 60
Early research (Phase 1)Study completedNCT00161187
What this trial is testing

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

Who this might be right for
Cancer
University of Medicine and Dentistry of New Jersey 37
Testing effectiveness (Phase 2)Study completedNCT03147404
What this trial is testing

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Who this might be right for
Neuroendocrine Carcinoma, Grade 3
Samsung Medical Center 14
Testing effectiveness (Phase 2)WithdrawnNCT02763761
What this trial is testing

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Who this might be right for
Renal Cell CarcinomaMelanomaLung Cancer
Bristol-Myers Squibb
Testing effectiveness (Phase 2)Active Not RecruitingNCT04471727
What this trial is testing

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)

Who this might be right for
Small-Cell Lung CancerNeuroendocrine Carcinoma
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 232
Not applicableLooking for participantsNCT06981455
What this trial is testing

Life Following Excision of Neuroendocrine Tumors

Who this might be right for
Neuroendocrine (NE) TumorsNeuroendocrine Tumor GEP Grade 1-3
Sunnybrook Health Sciences Centre 246
Testing effectiveness (Phase 2)Ended earlyNCT02709889
What this trial is testing

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Who this might be right for
Malignant MelanomaMedullary Thyroid CancerGlioblastoma+5 more
AbbVie 200
40